Modulation of Lamina Cribrosa Matrix Remodeling in POAG
Principal Investigator
Colm O'Brien, MD, FRCS
Mater Misericordiae Hospital (Ireland)
Dublin, Ireland
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2007 - March 31, 2009
Grant ID
G2007051
Goals
This project intends to test the hypothesis of that the use of novel anti-fibrotic therapies will reduce the damage done in glaucoma to the retinal ganglion cells thereby alleviating the resultant loss of vision.
Summary
At present, glaucoma represents the most common form of irreversible blindness in the western world. The exact causes of the different types of glaucoma are not fully understood but in one common form, primary open angle glaucoma it is believed that mechanical strain induced by elevated intra-ocular pressure plays a part. This causes changes in the connective tissue of the lamina cribrosa, which is where the optic nerves exit the eye. Previous evidence has shown that soluble growth factors such as the TGF- family can affect the extracellular composition of this tissue. By modulating the expression of the TGF- family we hope to change the connective tissue composition of the lamina cribrosa and thereby reduce the damage to the retinal ganglion cells and reduce loss of visual function.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
National Glaucoma Research
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear